0001209191-22-015804.txt : 20220303 0001209191-22-015804.hdr.sgml : 20220303 20220303180713 ACCESSION NUMBER: 0001209191-22-015804 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20220301 FILED AS OF DATE: 20220303 DATE AS OF CHANGE: 20220303 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Gruskin Daniel CENTRAL INDEX KEY: 0001863053 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38707 FILM NUMBER: 22710836 MAIL ADDRESS: STREET 1: 65 HAYDEN AVENUE STREET 2: 2ND FLOOR CITY: LEXINGTON STATE: MA ZIP: 02421 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: LogicBio Therapeutics, Inc. CENTRAL INDEX KEY: 0001664106 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 471514975 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 65 HAYDEN AVE STREET 2: 2ND FLOOR CITY: LEXINGTON STATE: MA ZIP: 02421 BUSINESS PHONE: 617-245-0399 MAIL ADDRESS: STREET 1: 65 HAYDEN AVE STREET 2: 2ND FLOOR CITY: LEXINGTON STATE: MA ZIP: 02421 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2022-03-01 0 0001664106 LogicBio Therapeutics, Inc. LOGC 0001863053 Gruskin Daniel C/O LOGICBIO THERAPEUTICS, INC. 65 HAYDEN AVE, FLOOR 2 LEXINGTON MA 02421 0 1 0 0 Chief Medical Officer Stock Option (right to buy) 0.70 2022-03-01 4 A 0 140000 0.00 A 2032-03-01 Common Stock 140000 140000 D The options were granted by LogicBio Therapeutics, Inc. (the "Company") pursuant to its 2018 Equity Incentive Plan. The options will vest over four years: 25% of the options will vest on the first anniversary of the grant date with the remaining 75% vesting in equal quarterly installments thereafter, subject to the Reporting Person's continued service with the Company on each vesting date. /s/ Andrea Paul, as Attorney-in-Fact 2022-03-03